The first half of 2025 has brought major developments in gastroenterology, spanning new drug approvals, trial data, and clinical guidance. Two major FDA approvals expanded the use of IL-23-targeted therapies in Crohn’s disease: mirikizumab (Omvoh) and guselkumab (Tremfya), both showing strong clinical efficacy across trials.
Trending
- Glowing Bacteria Pills Could Replace Colonoscopies and Detect Gut Disease (Discover Magazine)
- First-of-its-kind study may help explain why colorectal cancers are rising sharply in young people (CNN)
- Roche inks deal for rights to Freenome cancer tests outside US (Medtech Dive)
- GastroGPT Pioneering Specialized AI in Gastroenterology: Strengths, Pitfalls, and the Road to Clinical Integration (Journal of Gastroenterology and Hepatology)
- How the fall of Steward Health Care shaped private equity’s presence in hospitals (Healthcare Brew)
- 10 strategic options for physicians facing challenges in private medical practice (Medical Economics)
- GLP-1s May Improve Colon Cancer Outcomes (Medscape)
- Shore Capital Partners Announces the Merger of Reliant Healthcare and Care Fusion Rx to Form a Leading National Infusion Therapy Platform (Business Wire)
